Thermo-reversible in situ forming implant with nanostructured lipid carriers (NLC) as a delivery system for the administration of estradiol valerate
- 1 Downloads
A thermo-reversible in situ forming implant, based on the combination of Pluronic® F-127 and Pluronic® F-68 with nanostructured lipid carriers (NLC), was formulated with the aim of achieving the sustained release of estradiol valerate (EV). EV-loaded NLC, prepared by the hot high-pressure homogenization technique, presented an entrapment efficiency of 90 ± 2.9 %, a particle size (PS) of 122 ± 11.2 nm, a polydispersity index (PDI) of 0.344 ± 0.07, and a zeta potential (ZP) of − 10.5 ± 1.3 mV. Once obtained, NLC were then included in a thermo-reversible gel (EV-loaded NLC gel), which was characterized by its rheological behavior, gelation temperature, and injectability. The in vitro release tests showed that the EV-loaded NLC gel delayed the release significantly, in comparison with a solution of the drug and with the EV-loaded NLC. The EV-loaded NLC gel and a commercially available suspension containing estradiol were administered parenterally to rabbits. A 16.8-fold greater AUC and a 40-fold higher Cmax were obtained with the EV-loaded NLC gel, compared to the commercial suspension. A rapid initial release of EV in vivo, from the EV-loaded NLC gel, suggests that it is necessary to adjust the ratio of the copolymers or to include in the gel an additive that improves gelation time and gel strength, in order to achieve a sustained release. An interesting observation was that the in vitro profile, which has a three-phase behavior, coincides with what was observed in the in vivo study.
KeywordsEstradiol valerate Nanostructured lipid carriers Thermo-reversible Hormone, replacement therapy Pluronic
The authors are grateful for the financial support provided by CONACyT (Mexico), PIAPI/UNAM (Ref. 1803), and PAPIIT/UNAM (Ref. IN226119). Likewise, they want to thank Dr. Gabriel Araujo-Silva for their excellent assistance with rabbit work.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
The experiments comply with the current laws of the country in which they were performed.
“All institutional and national guidelines for the care and use of laboratory animals were followed.”
- 3.Gaffield ME, Curtis KM, Mohllajee AP, Peterson HB. Medical eligibility criteria for new contraceptive methods: combined hormonal patch, combined hormonal vaginal ring and the etonogestrel implant. Contraception. 2006;73:134–44. https://doi.org/10.1016/j.contraception.2005.08.002.CrossRefPubMedGoogle Scholar
- 5.Elkasabgy NA, Abdel-Salam FS, Mahmoud AA, Basalious EB, Amer MS, Mostafa AA, et al. Long lasting in situ forming implant loaded with raloxifene HCl: an injectable delivery system for treatment of bone injuries. Int J Pharm. 2019;571:118703. https://doi.org/10.1016/j.ijpharm.2019.118703.CrossRefPubMedGoogle Scholar
- 6.Kamali H, Khodaverdi E, Hadizdeh F, Yazdian-Robati R, Haghbin A, Zohuri G. An in-situ forming implant formulation of naltrexone with minimum initial burst release using mixture of PLGA copolymers and ethyl heptanoate as an additive: in vitro, ex vivo, and in vivo release evaluation. J Drug Deliv Sci Technol. 2018;47:95–105. https://doi.org/10.1016/j.jddst.2018.06.027.CrossRefGoogle Scholar
- 10.Escobar-Chávez JJ, López-Cervantes M, Naik A, Kalia YN, Quintanar-Guerrero D, Ganem-Quintanar A. Applications of thermos-reversible Pluronic F-127 gels in pharmaceutical formulations. J Pharm Pharmaceut Sci. 2006;9:339–58.Google Scholar
- 11.Nie S, Wendy Hsiao WL, Pan W, Yang Z. Thermoreversible Pluronic® F127-based hydrogel containing liposomes for the controlled delivery of paclitaxel: in vitro drug release, cell cytotoxicity, and uptake studies. Int J Nanomedicine. 2011;6:151–66. https://doi.org/10.2147/IJN.S15057.CrossRefPubMedPubMedCentralGoogle Scholar
- 13.Din F, Mustapha O, Kim DW, Rashid R, Park JH, Choi JY, et al. Novel dual-reverse thermosensitive solid lipid nanoparticle-loaded hydrogel for rectal administration of flurbiprofen with improved bioavailability and reduced initial burst effect. Eur J Pharm Biopharm. 2015;94:64–72. https://doi.org/10.1016/j.ejpb.2015.04.019.CrossRefPubMedGoogle Scholar
- 22.Shah R, Eldridge D, Palombo E, Harding I. Optimization and stability assessment of solid lipid nanoparticles using particle size and zeta. J Phys Sci. 2014;25(1):59–75 ISSN: 1675-3402.Google Scholar
- 23.Malvern Instruments Ltd. (2004). Zetasizer Nano Series. User Manual. United Kingdom.Google Scholar
- 24.ACOFARMA. (n.d.), Security file. Review date 2, 12, 2016. http://www.acofarma.com/admin/uploads/descarga/15986212812e7f9ed43f9114bfee18c189e8fbcd574f/main/files/Estradiol%20valerato.pdf
- 25.Rowe RC, Sheskey PJ, Quinn ME. Handbook of Pharmaceutical Excipients. 6th ed. London: Pharmaceutical Press; 2009. ISBN 978 0 85369 792 3Google Scholar
- 31.Akkari ACS, Boava Papini JZ, Grcia GK, Dias Franco MKK, Cavalcanti LP, Gasperini A, et al. Poloxamer 407/188 binary thermosensitive hydrogels as delivery systems for infiltrative local anesthesia: Physico-chemical characterization and pharmacological evaluation. Mater Sci Eng C. 2016;68:299–307. https://doi.org/10.1016/j.msec.2016.05.088.CrossRefGoogle Scholar